Allergan plc (AGN) Shares Sold by Sentry Investment Management LLC
Sentry Investment Management LLC reduced its position in Allergan plc (NYSE:AGN) by 2.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 21,449 shares of the company’s stock after selling 640 shares during the quarter. Sentry Investment Management LLC’s holdings in Allergan were worth $4,086,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AGN. Thompson Siegel & Walmsley LLC lifted its stake in shares of Allergan by 3,032.4% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 877,740 shares of the company’s stock valued at $146,337,000 after purchasing an additional 849,719 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Allergan by 27,066.5% during the 2nd quarter. Renaissance Technologies LLC now owns 787,828 shares of the company’s stock valued at $131,347,000 after buying an additional 784,928 shares during the period. Mainstay Capital Management LLC ADV raised its holdings in shares of Allergan by 13,097.2% during the 2nd quarter. Mainstay Capital Management LLC ADV now owns 675,039 shares of the company’s stock valued at $4,288,000 after buying an additional 669,924 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Allergan by 16.3% during the 2nd quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock valued at $796,712,000 after buying an additional 668,343 shares during the period. Finally, Orbimed Advisors LLC raised its holdings in shares of Allergan by 85.4% during the 2nd quarter. Orbimed Advisors LLC now owns 1,286,205 shares of the company’s stock valued at $214,436,000 after buying an additional 592,600 shares during the period. 77.55% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts recently commented on the company. Mizuho reiterated a “hold” rating and set a $194.00 target price on shares of Allergan in a report on Monday, July 30th. Cantor Fitzgerald reiterated a “hold” rating and set a $180.00 target price on shares of Allergan in a report on Friday, September 14th. ValuEngine upgraded Allergan from a “sell” rating to a “hold” rating in a report on Tuesday, October 23rd. Piper Jaffray Companies set a $164.00 target price on Allergan and gave the company a “hold” rating in a report on Monday, September 17th. Finally, Cowen set a $255.00 target price on Allergan and gave the company a “buy” rating in a report on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. Allergan currently has an average rating of “Buy” and an average price target of $210.18.
Allergan (NYSE:AGN) last posted its quarterly earnings data on Tuesday, October 30th. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.21. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.89 billion. During the same period in the previous year, the business earned $4.15 EPS. Allergan’s revenue for the quarter was down 3.0% compared to the same quarter last year. On average, equities analysts forecast that Allergan plc will post 16.42 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 14th. Shareholders of record on Tuesday, November 13th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, November 9th. This represents a $2.88 annualized dividend and a yield of 1.74%. Allergan’s dividend payout ratio is presently 17.61%.
In other news, Director Joseph H. Boccuzi bought 900 shares of the firm’s stock in a transaction dated Thursday, August 30th. The stock was bought at an average price of $190.59 per share, for a total transaction of $171,531.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Christopher J. Coughlin bought 10,000 shares of the firm’s stock in a transaction dated Thursday, September 6th. The stock was purchased at an average price of $190.64 per share, with a total value of $1,906,400.00. The disclosure for this purchase can be found here. 0.36% of the stock is owned by insiders.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Featured Article: How to interpret a stock’s beta number
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.